PAT SM6

Drug Profile

PAT SM6

Alternative Names: PAT-SM6; SM-6

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoMab GmbH
  • Developer Patrys
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; LDL lipoprotein modulators; Molecular chaperone GRP78 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • No development reported Malignant melanoma

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Malignant-melanoma in Australia (IV, Infusion)
  • 22 Sep 2015 PAT SM6 is still in phase-I/II development for Multiple myeloma in Germany
  • 18 Feb 2015 Patrys has patent protection for PAT SM6 in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top